2012-05-08 15:15 Corline Systems AB On the 5th annual conference for the the Scandinavian Soc. of Biomaterials, researchers from the Uppsala University presented preliminary results from an on-going project showing that the Corline Heparin Conjugate(CHC) have ability to reduce thrombogenicity and increase remodelling at the vascular injury site. They conclude that CHC is an interesting candidate for treatement of vascular damage.
